Orphan Designation Requests To Get Slower US FDA Reviews
This article was originally published in SRA
The US Food and Drug Administration has extended its deadline for delivering an orphan drug designation decision, placing more pressure on sponsors to ensure requests contain no problems from the start.
You may also be interested in...
Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.